Female Fertility Assessment Panel

Female Fertility Assessment Panel is a blood test that measures seven hormones connected with ovarian function, menstrual cycle regulation, thyroid function, and reproductive planning: thyroid-stimulating hormone (TSH), estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, testosterone, and anti-Müllerian hormone (AMH). The panel can provide useful laboratory context when fertility is being assessed, but it is not a complete fertility evaluation and cannot determine by itself whether natural conception will occur.

The results are most useful when interpreted together with age, menstrual cycle pattern, the exact cycle day on which the sample was collected, symptoms, medical history, medication and hormonal contraceptive use, previous pregnancies, and any earlier fertility investigations. Depending on the reason for testing, a broader evaluation may also include confirmation of ovulation, pelvic ultrasound, antral follicle count, assessment of the uterus and fallopian tubes, and semen analysis for the male partner.

What the included hormones can show

• FSH is produced by the pituitary gland and supports the growth of ovarian follicles. A basal FSH result is usually interpreted together with estradiol during the early follicular phase. One result can vary between cycles and should not be treated as a standalone measure of fertility.
• Estradiol is the main estrogen produced by developing ovarian follicles. Early-cycle estradiol helps place FSH in context because an elevated estradiol level can make an FSH result appear lower than it otherwise would.
• LH contributes to follicle maturation and triggers ovulation later in the cycle. Its concentration changes substantially during the menstrual cycle, so the cycle day is essential for interpretation.
• Prolactin helps regulate breast milk production and also interacts with reproductive hormone signaling. Persistently elevated prolactin can be associated with irregular or absent ovulation, although temporary increases may occur because of sleep, stress, exercise, or the blood collection process.
• TSH reflects signaling between the pituitary gland and thyroid. Thyroid disorders can affect menstrual regularity and ovulatory function, so TSH may help identify a thyroid-related factor that requires further assessment.
• Testosterone is present in women in smaller amounts and forms part of androgen assessment. The result may be relevant when menstrual irregularity, acne, increased body or facial hair, or a possible ovulatory disorder is being evaluated, but it does not measure fertility directly.
• AMH is produced by small ovarian follicles and is used as a marker of the remaining follicular pool. It is particularly useful for estimating likely ovarian response to stimulation. AMH does not measure egg quality, does not confirm ovulation, and cannot independently predict the chance or timing of natural conception.

Why the menstrual cycle day matters

For a baseline ovarian reserve assessment, FSH and estradiol are commonly measured together during the early follicular phase, usually on cycle days 2 to 4. Day 1 is the first day of full menstrual bleeding, not light spotting. LH is also easier to interpret as a baseline value during this phase because it rises around ovulation. If the panel is requested for another clinical reason, a different sampling day may be appropriate.

AMH can generally be measured on any cycle day because it varies less across the cycle than FSH, estradiol, or LH. This flexibility does not remove the need for clinical interpretation. Hormonal contraception can suppress AMH in some women, and results may also be influenced by age, ovarian surgery, endometriosis, chemotherapy, and individual biological variation.

Women with very irregular cycles, prolonged absence of periods, pregnancy, recent childbirth, or breastfeeding should clarify the purpose and timing of testing before the sample is collected. In these situations, standard cycle-day reference patterns may not apply.

Who may consider this panel

The panel may be considered by women who are planning pregnancy and have a specific reason for hormonal assessment, women with irregular or absent menstrual cycles, those who have not conceived within the expected timeframe, and patients preparing for a fertility consultation or assisted reproduction pathway. It may also be useful when ovarian reserve needs to be discussed before ovarian surgery, fertility preservation, or treatment that may affect ovarian function.

A laboratory panel should not be used as a general pass or fail fertility test. In women younger than 35, a formal fertility evaluation is generally considered after 12 months of regular unprotected intercourse without pregnancy. From age 35, evaluation is usually considered after 6 months, and earlier assessment may be appropriate when cycles are irregular, there is a known reproductive condition, previous pelvic surgery, endometriosis, a history of gonadotoxic treatment, or another relevant risk factor.

How the testing process usually works

Step 1: Confirm the purpose and timing

Before testing, confirm whether the panel is intended as an early-cycle baseline, part of an infertility evaluation, or preparation for treatment. Record the first day of the current menstrual period and the usual cycle length.

Step 2: Review medications and preparation

Prepare a list of prescription medicines, supplements, fertility medications, thyroid treatment, and hormonal contraception. Do not stop prescribed treatment without medical advice. Because prolactin is included, sampling is best planned in the morning, approximately 1 to 2 hours after waking, after a period of rest. Follow any additional preparation instructions provided when the test is arranged.

Step 3: Blood collection

A venous blood sample is collected. Serum or plasma is then used to measure the included hormones. The blood draw itself usually takes only a few minutes.

Step 4: Laboratory report and interpretation

The report lists each hormone result with the laboratory reference interval. The exact report turnaround should be confirmed when arranging the panel. Interpretation should account for age, cycle day, symptoms, medication use, and the clinical question. A result outside the reference interval may need confirmation or targeted follow-up rather than immediate conclusions.

What the results can and cannot answer

The panel can help identify hormone patterns that may justify a more focused reproductive, gynecologic, or endocrine evaluation. It may support discussion of ovarian reserve, menstrual cycle regulation, possible ovulatory dysfunction, prolactin-related changes, thyroid function, and androgen balance.

It cannot assess fallopian tube patency, uterine anatomy, sperm factors, embryo development, implantation, or every cause of infertility. It also cannot determine the quality of the remaining eggs. Age remains a major factor in reproductive potential, and a normal AMH result does not guarantee pregnancy. Likewise, a low AMH result does not mean that natural conception is impossible.

Practical next step through ZagrebMed

When sending an inquiry through ZagrebMed, include your age, the first day and usual length of your menstrual cycle, whether cycles are regular, current medications or hormonal contraception, how long you have been trying to conceive if applicable, and any previous hormone results, ultrasound reports, fertility treatment records, or relevant diagnoses. This information helps clarify the most appropriate sampling day and whether the panel should be combined with a gynecologic consultation, ultrasound, or broader fertility assessment.